---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-105004"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2022-04-14T23:59:59+00:00"
generated_at: "2026-06-26T07:25:06.227317+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Magenta Therapeutics prioritizes MGTA-117, cuts workforce 14%, extends cash runway into Q2 2024

## Summary
- MGTA-117 Phase 1/2 trial shows encouraging early data: well-tolerated with no significant adverse events, early pharmacodynamic signals.
- Company reduces workforce by 14% and extends cash runway into Q2 2024 through spending prioritization.
- Magenta to disclose summary of clinical observations from initial MGTA-117 patients in Q1 2022 earnings release in early May.
- De-prioritizing other portfolio investments, pausing MGTA-145 dosing optimization trial in healthy subjects.

## SEC filing metadata
- accession: 0001193125-22-105004
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2022-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000119312522105004/0001193125-22-105004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000119312522105004/d343288d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-105004
- JSON: https://secwatch.observer/filing/0001193125-22-105004.json
- Plain text: https://secwatch.observer/filing/0001193125-22-105004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.